CXCL13 and ovarian cancer: Combining an oral FAK inhibitor with TIGIT-blocking antibody immunotherapy increased TILs and CXCL13 levels, leading to TLS formation and prolonged survival in experimental mouse models of aggressive ovarian cancer (58).